The New Mexico DPA office opened in 2000. Since then, we have helped enact a range of drug policy reforms through the legislative process. Our focus areas include:
DPA's New Mexico State Director, Emily Kaltenbach, chaired the city of Santa Fe's Municipal Drug Strategy Task Force. In February 2020, the task force released a report that provides a roadmap for the city to move forward with drug strategies that focus on public health and safety.
"Santa Fe is another example of bold municipal leadership. The work of the Santa Fe Municipal Drug Strategy Task Force demonstrates how cities can step up and implement innovative drug policies rooted in science, compassion, and public health. Even when the federal government fails to act, cities can.” - Emily Kaltenbach
In 2021, we successfully supported the legalization of cannabis. The new law goes into effect on June 29th, 2021; sales are to start no later than April 1, 2022. DPA is working to ensure equity and social justice are included in the implementation of the new law.
DPA is committed to reducing the harms associated with drug use in New Mexico. Our priorities include authorizing overdose prevention programs, expanding access to drug checking services, and establishing an injectable opioid treatment program.
Drug arrests have led to unprecedented levels of incarceration in New Mexico, especially for people of color. We advocate for the decriminalization of drug use and possession and municipal drug strategies that will move small towns and cities from criminal justice structures towards public health structures.
(505) 983-3277 ph
nm "at" drugpolicy.org